We participate in many activities to support sustainable health care systems and improve standards of care worldwide.
Even with free drug programs or other forms of funding, patients' access to treatment can still be impeded by other issues: logistical and bureaucratic difficulties, inadequate health care facilities, or simply lack of knowledge. So in addition to donating our products, Sanofi Genzyme works in many ways to build and maintain the many avenues necessary for medical care.
Global reach, local involvement
Our worldwide operations serve more than 100 countries, with a global infrastructure that includes research and development, manufacturing, regulatory affairs, medical affairs, and more. This network of expertise, plus our on-the-ground relationships with local stakeholders, enables us to bring products to patients in every corner of the globe. We work closely with governments to facilitate approval of our treatments. In countries with established health care systems, we work with public and private insurers to secure coverage and reimbursement. In developing countries and emerging markets, we lend our experience to help physicians and local authorities build sustainable health care networks that can deliver and pay for critical treatment. Around the world, we collaborate with health care providers, humanitarian organizations, and other local partners to overcome barriers to treatment.
- Hand-in-hand with developing therapies is our commitment to improving patient access to treatment.
- Through our humanitarian programs we provide several of our therapies free of charge to qualified patients in need.
Education and outreach
Our business was founded on treating diseases so rare that they are often unfamiliar even to many health care professionals. We are acutely aware of how important education and outreach are to identifying and effectively treating patients. Through our humanitarian programs and other initiatives, we work to raise awareness about the diseases we treat, educate both patients and the medical community, and advance research and quality of care.
- As one of the world's leading authorities on the group of rare genetic diseases called lysosomal storage disorders (LSDs), Sanofi develops educational materials for both patients and professionals to increase understanding about these diseases.
- Our programs provide healthcare providers expanded opportunities in clinical education, treatment experience and patient monitoring. Many times, our humanitarian programs serve as a physician’s first experience in treating an LSD.
- By establishing LSD registries - large multinational databases to which physicians contribute clinical data on patients—we help pool knowledge on rare diseases that would be otherwise difficult to study.
- We sponsor independent investigator research and provide grants for continuing medical education and research fellowships in our areas of focus.
- We partner with local patient organizations around the world to support and advocate for the needs of their patient communities.